Johnson & Johnson discontinues phase II field study of JNJ 1802 for dengue virus
Johnson & Johnson announced it is discontinuing the Phase II field study (NCT05201794) evaluating the efficacy of investigational antiviral candidate mosnodenvir for the prevention of dengue virus in adults aged 18-65 years
The decision to discontinue this study is part of a strategic reprioritization of the Company’s Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.
Efficacy data from the Phase II field study will be available once the final data analyses, which are now underway, are complete. Study investigators have been notified of the discontinuation. All participants have completed the study per protocol and will be notified of the results once they are ready.
Mosnodenvir (formerly JNJ 1802) was shown to be safe and well tolerated in previous Phase 1 and Phase IIa clinical studies. Results from the Phase IIa human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins